IDEXX Laboratories Launches Cornerstone® 6.2 Practice Management System [Trade]

WESTBROOK, Maine, January 06, 2006—IDEXX Computer Systems, a division of IDEXX Laboratories, Inc. (NASDAQ: IDXX), announces the availability of an enhanced version of its practice-management software in Cornerstone® 6.2. This You-Asked-For-It Customer Request Release incorporates the most sought-after changes in form and functions, including enhancements to the Compliance Assessment Tool™ for measuring, managing and improving patient wellness programs and support for the newly integrated CareCredit® No Interest Payment Plan.

Among the customer benefits included in IDEXX Cornerstone 6.2 are:

• protocol-based client and patient alerts in the Cornerstone Compliance Assessment Tool,
• IDEXX LabREXX®, a program that autogenerates requisitions for IDEXX Reference Laboratories, thus ensuring complete data accuracy and practice efficiency,
• enhanced diagnostic imaging features,
• the integration of CareCredit no interest client financing software,
• a wealth of new practice reports,
• new Invoicing, Estimating and Reminder system features,
• greater Internet integration, and
• easier handling of client correspondence.

"We wanted to start 2006 off with a Cornerstone release that incorporated features and functionality that practices have been telling us are missing from most practice-management systems," said John Wallace, division vice president of IDEXX Computer Systems. "By continually asking our customers what they want, we're better able to provide the tools that truly work for them. With IDEXX Cornerstone 6.2, we worked hard to combine innovative functionality, such as our compliance-management tools, with features veterinarians most need to care for their patients."

To request a free Cornerstone 6.2 demonstration disc or schedule a live demonstration at your practice, contact IDEXX Computer Systems Sales at 1-800-283-8386, option 2, or visit our Web site at www.idexx.com/cornerstone.

About IDEXX Laboratories

IDEXX Laboratories, Inc., is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and therapeutics. Our products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,000 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements

This press release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company's sales and marketing activities; the Company's ability to develop, license or obtain rights to new technologies; the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company's products; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company's inventories; the Company's ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2004 (PDF, 2.6 MB), and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 (PDF, 424 KB), in the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations."